Cargando…

Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. Median survival for metastatic patients is six to nine months and survivors beyond one year are exceptional. Pancreatic cancer is resistant to conventional chemotherapy and is often diagnosed at advanced stages. However, immuno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa Neves, Mafalda, Giakoustidis, Alex, Stamp, Gordon, Gaya, Andy, Mudan, Satvinder
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2015
Materias:	General Surgery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731256/ https://www.ncbi.nlm.nih.gov/pubmed/26870619 http://dx.doi.org/10.7759/cureus.435

Ejemplares similares

Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma
por: Giakoustidis, Alexandros, et al.
Publicado: (2018)

Tumor Biology: Is It Time to Redefine Unresectability? An Extraordinary Case of Gastroesophageal Junctional Adenocarcinoma
por: Gaya, Andy, et al.
Publicado: (2015)

Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity
por: Dalgleish, Angus G., et al.
Publicado: (2018)

Sporadic diffuse segmental interstitial cell of Cajal hyperplasia harbouring two gastric gastrointestinal stromal tumours (GIST) mimicking hereditary GIST syndromes
por: Neves, Mafalda Costa, et al.
Publicado: (2015)

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
por: Dalgleish, Angus G, et al.
Publicado: (2016)

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
por: Dalgleish, Angus G, et al.
Publicado: (2016)

Effective Downsizing of a Large Oesophageal Gastrointestinal Stromal Tumour with Neoadjuvant Imatinib Enabling an Uncomplicated and without Tumour Rupture Laparoscopic-Assisted Ivor-Lewis Oesophagectomy
por: Neofytou, Kyriakos, et al.
Publicado: (2015)

Two cases of gallbladder metastasis from renal cell carcinoma and review of literature
por: Costa Neves, Mafalda, et al.
Publicado: (2016)

Emergency Open Incarcerated Hernia Repair with a Biological Mesh in a Patient with Colorectal Liver Metastasis Receiving Chemotherapy and Bevacizumab Uncomplicated Wound Healing
por: Giakoustidis, Alexandros, et al.
Publicado: (2014)

IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer
por: Bilyard, Hilary, et al.
Publicado: (2014)

Long-term Disease-free Survival Following Combination Multi-visceral and Metastatic Resection with Neoadjuvant FOLFIRINOX for Pancreatic Adenocarcinoma: A Case Report
por: Sodergren, Mikael, et al.
Publicado: (2015)

Emergency Pancreatoduodenectomy with Preservation of Gastroduodenal Artery for Massive Gastrointestinal Bleeding due to Duodenal Metastasis by Clear Cell Renal Cell Carcinoma in a Patient with Celiac Artery Stenosis
por: Neofytou, Kyriakos, et al.
Publicado: (2014)

Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
por: Brunet, Laura Rosa, et al.
Publicado: (2015)

The Concept of Hormesis in Cancer Therapy – Is Less More?
por: Gaya, Andy, et al.
Publicado: (2015)

An Unusual Recurrence of Signet Ring Cell Gastric Adenocarcinoma Treated by Right Hemicolectomy, Pancreaticoduodenectomy, and IVC Resection: Controversies and Dilemmas of Following Standard Treatment Pathways
por: Sodergren, Mikael, et al.
Publicado: (2015)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

Treatment with IMM-101 induces protective CD8+ T cell responses in clinically relevant models of pancreatic cancer
por: Elia, Androulla, et al.
Publicado: (2013)

Editorial: Neuroendocrine tumors of the gastrointestinal tract, liver, and pancreas: current management and treatment strategies
por: Giakoustidis, Alexandros, et al.
Publicado: (2023)

Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Koffas, Apostolos, et al.
Publicado: (2023)

Tratado de entomología Imms
por: Richards, O. W.
Publicado: (1983)

Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis
por: Freitas, Elisangela Oliveira, et al.
Publicado: (2015)

Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced Pancreatic Cancer
por: van ‘t Land, Freek R., et al.
Publicado: (2022)

Combined ultrasonic aspiration and saline-linked radiofrequency precoagulation: a step toward bloodless liver resection without the need of liver inflow occlusion: analysis of 313 consecutive patients
por: Felekouras, Evangelos, et al.
Publicado: (2014)

Re-measurement of $^{32}$Ar to test the IMME
por: Kreim, S
Publicado: (2012)

Effects of Total Pancreatectomy on Survival of Patients With Pancreatic Ductal Adenocarcinoma: A Population-Based Study
por: Shao, Weiwei, et al.
Publicado: (2021)

VaccImm: simulating peptide vaccination in cancer therapy
por: von Eichborn, Joachim, et al.
Publicado: (2013)

Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles
por: Ilyinskii, Petr O., et al.
Publicado: (2021)

Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
por: Chen, Fei, et al.
Publicado: (2022)

Development and In Vitro–In Vivo Correlation Evaluation of IMM-H014 Extended-Release Tablets for the Treatment of Fatty Liver Disease
por: Zhang, Chi, et al.
Publicado: (2023)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study
por: Song, Lishan, et al.
Publicado: (2022)

Rectal Signet Ring Cell Carcinoma: Post-Chemoradiotherapy Evaluation by MRI and Corresponding to Pathology
por: Zhou, Yin, et al.
Publicado: (2022)

Pancreatico-gastric fistula arising from IPMN associated with ductal adenocarcinoma of the pancreas: a case report and a literature review
por: AbuDalu, M., et al.
Publicado: (2023)

ImmGen report: sexual dimorphism in the immune system transcriptome
por: Gal-Oz, Shani Talia, et al.
Publicado: (2019)

Adaptive Federated IMM Filter for AUV Integrated Navigation Systems
por: Lyu, Weiwei, et al.
Publicado: (2020)

Extended Robotic Pulmonary Resections
por: Scheinerman, Joshua A., et al.
Publicado: (2021)

Prognostic Value of the Distribution of Lymph Node Metastasis in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy
por: Chen, Bin, et al.
Publicado: (2021)

Adding Consolidation Capecitabine to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Propensity-Matched Comparative Study
por: Fang, Yifang, et al.
Publicado: (2022)

Total neoadjuvant therapy or standard chemoradiotherapy for locally advanced rectal cancer: A systematic review and meta-analysis
por: Ma, Zhou, et al.
Publicado: (2022)

Clinical outcome comparison of laparoscopic radical antegrade modular pancreatosplenectomy vs. laparoscopic distal pancreatosplenectomy for left-sided pancreatic ductal adenocarcinoma surgical resection
por: Niu, Nan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qrukrv1is3upjvov4dh6ap4nsv